Visitors Now:
Total Visits:
Total Stories:
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Vaxil Bio encouraged by cancer drug progress on two fronts

Wednesday, November 30, 2016 8:49
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Vaxil Bio Ltd’ (CVE:VXL) has seen encouraging results from preliminary pre-clinical work on the use of its cancer treatment Immucin in combination with checkpoint inhibitors.

Vaxil tested Immucin in combination with other immunotherapy modalities including checkpoint inhibitors PD1 and CTLA4.

PD-1 is a checkpoint protein on immune cells, called T cells, that stops them from from attacking other cells in the body, but some cancerous cells also have large amounts of PD-1 and can trick the body into leaving them alone.

New immunotherapy treatments such as Immucin are designed to help the immune system recognise these cancerous cells and destroy them.

There was also good progress in the use of Immucin as a neo-antigen, with potential to strongly stimulate the immune system, Vaxil said.

Neo-antigens are mutated proteins found only on the surface of cancer cells and have been shown to elicit a specific immune response against the tumor.

If Immucin can be provoke a robust immune response in cancer patients it can be targeted to bind itself to cancerous cells.

Dr Chen, Vaxil’s VP of Operation, said new data was building in support Immucin acting as a neo-antigen, while as a combination therapy the drug had several key advantages that could make it an optimal candidate to use alongside another drug.

The drug has already received Orphan Drug Designation in the US and Europe and completed a successful Phase-I/II trial.

Story by ProactiveInvestors

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.